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Summary
Background Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive, fatal motor neuron disease with a 
variable natural history. There are no accurate models that predict the disease course and outcomes, which complicates 
risk assessment and counselling for individual patients, stratification of patients for trials, and timing of interventions. 
We therefore aimed to develop and validate a model for predicting a composite survival endpoint for individual 
patients with ALS.
Methods We obtained data for patients from 14 specialised ALS centres (each one designated as a cohort) in Belgium, 
France, the Netherlands, Germany, Ireland, Italy, Portugal, Switzerland, and the UK. All patients were diagnosed in the 
centres after excluding other diagnoses and classified according to revised El Escorial criteria. We assessed 16 patient 
characteristics as potential predictors of a composite survival outcome (time between onset of symptoms and non-
invasive ventilation for more than 23 h per day, tracheostomy, or death) and applied backward elimination with 
bootstrapping in the largest population-based dataset for predictor selection. Data were gathered on the day of diagnosis 
or as soon as possible thereafter. Predictors that were selected in more than 70% of the bootstrap resamples were used 
to develop a multivariable Royston-Parmar model for predicting the composite survival outcome in individual patients. 
We assessed the generalisability of the model by estimating heterogeneity of predictive accuracy across external 
populations (ie, populations not used to develop the model) using internal–external cross-validation, and quantified 
the discrimination using the concordance (c) statistic (area under the receiver operator characteristic curve) and 
calibration using a calibration slope.
Findings Data were collected between Jan 1, 1992, and Sept 22, 2016 (the largest data-set included data from 
1936 patients). The median follow-up time was 97·5 months (IQR 52·9–168·5). Eight candidate predictors entered 
the prediction model: bulbar versus non-bulbar onset (univariable hazard ratio [HR] 1·71, 95% CI 1·63–1·79), age at 
onset (1·03, 1·03–1·03), definite versus probable or possible ALS (1·47, 1·39–1·55), diagnostic delay (0·52, 
0·51–0·53), forced vital capacity (HR 0·99, 0·99–0·99), progression rate (6·33, 5·92–6·76), frontotemporal dementia 
(1·34, 1·20–1·50), and presence of a C9orf72 repeat expansion (1·45, 1·31–1·61), all p<0·0001. The c statistic for 
external predictive accuracy of the model was 0·78 (95% CI 0·77–0·80; 95% prediction interval [PI] 0·74–0·82) and 
the calibration slope was 1·01 (95% CI 0·95–1·07; 95% PI 0·83–1·18). The model was used to define five groups with 
distinct median predicted (SE) and observed (SE) times in months from symptom onset to the composite survival 
outcome: very short 17·7 (0·20), 16·5 (0·23); short 25·3 (0·06), 25·2 (0·35); intermediate 32·2 (0·09), 32·8 (0·46); 
long 43·7 (0·21), 44·6 (0·74); and very long 91·0 (1·84), 85·6 (1·96).
Interpretation We have developed an externally validated model to predict survival without tracheostomy and 
non-invasive ventilation for more than 23 h per day in European patients with ALS. This model could be applied to 
individualised patient management, counselling, and future trial design, but to maximise the benefit and prevent 
harm it is intended to be used by medical doctors only.
Funding Netherlands ALS Foundation.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Introduction
Neurodegenerative diseases impose an enormous 
clinical and economic burden on patients and health 
systems.1 Development of disease-modifying therapies 
and strategies for effective palliative care have been 
limited by disease heterogeneity and the presence of 
overlapping phenotypes.2 Therefore, models that can 
reliably predict outcomes at an individual patient level 
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could become important factors in a precision-medicine 
approach by improving the potential for prognostic 
counselling, stratification of patients for trials, and 
timing of interventions.2
Amyotrophic lateral sclerosis (ALS) is one of the most 
devastating neurodegenerative diseases. It predominantly 
affects motor neurons in the brain and spinal cord, 
leading to weakness of voluntary muscles.3,4 Muscle 
weakness progresses gradually, spreading from a site of 
clinical onset; patients eventually become paralysed and 
die, usually as the result of respiratory failure.3,4 The 
clinical features of ALS are heterogeneous: the disease 
can occur at any adult age, up to 15% of patients develop 
frontotemporal dementia,5 and 10–15% of patients have a 
family history of ALS or frontotemporal dementia.4
Survival for patients with ALS varies greatly, ranging 
from several months to more than 10 years. Determinants 
of survival at group level have been studied extensively:6 
patient characteristics such as older age at onset of 
symptoms, the presence of frontotemporal dementia, or 
a repeat expansion in C9orf72 have been associated with 
shorter survival.6,7 Unfortunately, despite the well 
documented natural history of ALS,3,6 prediction of 
survival in individual patients remains elusive. It is 
important that such risk predictions are sufficiently 
accurate across different settings and populations. The 
development and validation of such models is, however, 
challenging because few large datasets with individual 
participant data and adequate follow-up times are 
available.8–10
We therefore analysed clinical, cognitive, and genetic 
data of patients with ALS from ALS centres in Europe 
with a view to predicting a composite survival outcome—
time between onset of symptoms and non-invasive 
ventilation for more than 23 h per day, tracheostomy, or 
death—for individual patients on the day of diagnosis. 
We aimed to develop and externally validate a prediction 
model in multiple cohorts.
Methods
Study design and participants
We did a two-stage study using clinical, cognitive, and 
genetic data for patients with ALS from 14 specialised 
ALS centres (each one designated as a cohort) in Belgium, 
Research in context
Evidence before this study
Prediction of survival in individual patients with amyotrophic 
lateral sclerosis (ALS) is important but remains elusive. 
We searched PubMed without language restrictions using the 
terms “([amyotrophic lateral sclerosis] OR [motor neuron 
disease]) AND [survival] OR [mortality] OR [prognosis] OR 
[prognostic factor] OR [prediction model])” for articles on 
validated models that predict survival at an individual level and 
articles on clinical, cognitive, and genetic predictors of survival 
in ALS, published between Jan 1, 1960, and Dec 31, 2017. We 
searched for well studied predictors of survival that can be 
collected during diagnostic work-up and excluded factors that 
require longitudinal assessments (eg, slope of forced vital 
capacity) or that are rare (eg, SOD A4V mutations). We identified 
16 variables as predictors of survival in ALS in at least one 
peer-reviewed article, but replication was frequently absent, 
outcomes of studies were contradictory, and studies used 
different sets of covariates in multivariable analyses or adopted 
different variable definitions, which complicated a formal 
synthesis of previous findings. Two studies about prediction of 
disease progression in ALS (but not survival) were identified. 
These studies used data from 1822 and 3742 patients from the 
Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) 
database. This database includes patients from 23 clinical trials, 
but not from population-based studies or patient registries. We 
identified no sufficiently powered, externally validated, 
prediction models of survival in individual patients with ALS.
Added value of this study
In our study of 11 475 patients with ALS from 14 European ALS 
centres, we derived and validated, according to the TRIPOD 
guidelines, a multivariable model for the prediction of survival 
without tracheostomy or non-invasive ventilation for more 
than 23 h per day, for individual patients, based on clinical, 
cognitive, and genetic predictors that were defined at 
diagnosis. Most of these predictors can be collected cheaply, 
simply, and non-invasively, rendering them useful for the 
assessment of individual prognosis in an outpatient clinic 
setting. We assessed the external validity of our model across 
several populations, and showed that it had a probability of 
more than 95% for good performance. We defined 
five subgroups of patients with distinctive survival times 
(very short, short, intermediate, long, and very long), and 
illustrated the clinical applicability of our model to individual 
patients. All parameters and equations of our model are 
provided in our appendix to allow improvement of predictions 
through continuing research on other prognostic factors or 
outcome measures.
Implications of all the available evidence
Our study proposes a set of independent predictors of survival 
without tracheostomy or non-invasive ventilation for more 
than 23 h per day in patients with ALS and provides a validated 
prediction model. To minimise the risk of potential harm to 
patients if the prediction they receive is shorter than expected, 
the online model will be accessible only to medical doctors, who 
have to register and sign in before access is provided. We 
encourage implementation of the model in evidence-based, 
tailored counselling of individual patients and their caregivers, 
and in multidisciplinary care practices, by facilitating the 
selection of appropriate care pathways (eg, frequency of 
consultations involving specific disciplines), and in innovative 
trial design, by refining inclusion and exclusion criteria, 
stratification, and subgroup analyses.
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France, the Netherlands, Germany, Ireland, Italy, 
Portugal, Switzerland, and the UK. In the first stage, 
predictor selection was done in the largest cohort, with 
data from consecutive incident patients, diagnosed with 
ALS according to the revised El Escorial criteria, who 
participated in an ongoing prospective, population-based 
study in the Netherlands between Jan 1, 2006, and 
March 31, 2015.11 In the second stage, data for identified 
predictors and survival outcomes were requested from 
13 other centres to develop and externally validate the 
model. All patients were diagnosed in the centres after 
excluding other diagnoses, and classified according to the 
revised El Escorial criteria.12 Written informed consent 
was obtained from all participants and institutional 
review boards approved this study (appendix). The study 
is reported in accordance with the TRIPOD guidance for 
transparent reporting of prediction models.10
Procedures
Survival analyses in ALS research generally use 
composite endpoints (ie, events) comprising both death 
and respiratory events.13,14 In our study, survival was 
defined as time between onset of symptoms and our 
composite endpoint of non-invasive ventilation for more 
than 23 h per day, or tracheostomy, or death. We assessed 
ten clinical, four cognitive, and two genetic characteristics. 
All predictors were selected on the basis of a PubMed 
search.
Clinical predictors were sex, site of onset (spinal vs bulbar), 
age at onset of weakness or bulbar symptoms, revised El 
Escorial criteria (definite vs probable or possible ALS),12 
diagnostic delay (time from onset of weakness or bulbar 
symptoms to diagnosis), forced vital capacity (FVC; 
percentage of predicted based on normative values for age, 
sex, and body height), progression rate defined by the 
slope on the revised ALS Functional Rating Scale 
(ALSFRS-R),15 premorbid body-mass index (BMI),16 current 
smoking,17 and cigarette pack-years.6
Cognitive predictors were the presence of 
frontotemporal dementia according to the Neary or 
Rascovsky criteria,18 and scores on the verbal fluency 
index,19 the Frontal Assessment Battery,20 and the ALS 
Frontotemporal Dementia Questionnaire (ALSFTD-Q).21 
For the verbal fluency index participants were asked to 
name as many words as possible beginning with the 
letter D in 3 min, following which the participants were 
instructed to read aloud the generated words. The index 
was calculated as the number of words generated divided 
by the time needed to read them aloud. The frontal 
assessment battery is a bedside test comprising six tasks 
(maximum of 3 points per task) measuring 
conceptualisation, mental flexibility, motor programming, 
sensitivity to interference, inhibition control, and 
environmental autonomy; this test is sensitive to frontal 
lobe dysfunction. The ALSFRS-Q is a 25-item 
questionnaire (maximum of 4 points per item) applied to 
a proxy (ie, a caregiver who is able to assess the patient’s 
behaviour) that is developed to screen for behavioural 
disturbances in the patient with ALS.
Genetic predictors were presence of a C9orf72 mutation, 
and presence of the minor allele homozygous genotype 
(C/C) of the UNC13A single nucleotide polymorphism, 
which were determined as previously described.7,22–24 
These two genetic predictors are the most frequent 
mutations in patients with ALS and were previously 
shown to be associated with survival outcomes.7,22
Data were gathered on the day of diagnosis or as soon 
as possible thereafter. The ALSFRS-R slope was 
determined as follows: (48 minus ALSFRS-R score)/(date 
of the ALSFRS-R score minus date of onset).15 ALSFTD-Q 
scores were trichotomised into no, mild, and severe 
behavioural impairment.21 A detailed overview of 
predictors is reported in the appendix.
All cohorts used the ALSFRS-R score, except the cohort 
in Oxford (UK), which used the unrevised version of the 
ALSFRS. The ten questions of the unrevised version are 
identical to the first ten questions of the ALSFRS-R, but 
the ALSFRS-R has two additional questions about 
respiration. The maximum score per question is 4, 
resulting in a maximum score of 48 for the ALSFRS-R 
and 40 for the ALSFRS. To be able to compare scores, we 
transformed the ALSFRS score to the ALSFRS-R score by 
multiplying by 1·2. Furthermore, all cohorts used FVC to 
measure respiratory function, except the cohort in 
Dublin (Ireland), which used sniff nasal inspiratory 
pressure (SNIP), which is known to be correlated with 
FVC.25 Based on patients in the Dublin cohort for whom 
we had information about both FVC and SNIP, we 
transformed SNIP data of all patients to FVC to allow 
comparability between cohorts.
We explored patient preferences with regard to 
knowing their personalised prognosis by doing an online 
survey in 242 Dutch patients with ALS (appendix).
Statistical analysis
We used a backward elimination procedure with 
bootstrapping to select predictors of the composite 
survival outcome (appendix).26 Predictors that were 
selected in more than 70% of the bootstrap resamples 
entered a multivariable prediction model.26 Data from the 
14 cohorts were combined using the internal–external 
cross-validation framework.27,28 This developed a model 
for predicting our composite survival endpoint in all but 
one cohort, after which its external validity was evaluated 
in the omitted cohort. The process was repeated for all 
14 cohorts (every cohort being omitted once), yielding 
multiple estimates of external validity for a given 
modelling strategy. A meta-analysis was done to assess 
the overall performance of the model and to identify 
sources of between-study heterogeneity,29 such as 
differences in survival time or differences in 
the definition of predictors between different cohorts, 
which might affect the generalisability of a model. The 
internal–external cross-validation framework thus 
See Online for appendix
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provided a means to learn about the generalisability of the 
model across different settings and populations.
For model development, we used multivariable 
Royston-Parmar survival models30 rather than Cox 
survival models, to facilitate the calculation of absolute 
risks in individual patients when implementing the 
model in clinical practice (appendix). We assumed a 
common baseline hazard for all cohorts, but also reported 
values of cohort-specific baseline hazard functions, 
which might help to tailor predictions to different 
populations. We used fractional polynomials to identify 
non-linear relationships with our composite survival 
endpoint.31 Missing values were multiply imputed using 
multilevel joint modelling techniques in accordance with 
previous publications (appendix).32,33
For model validation, we assessed discrimination (ie, the 
ability to differentiate between patients who reached our 
composite endpoint and those who did not) and calibration 
(ie, the agreement between observed and predicted times 
to our composite endpoint). Discrimination was quantified 
using the concordance (c) statistic, which is the area under 
the receiver operator characteristic (ROC) curve generalised 
to all possible survival timepoints as defined by the 
composite endpoint. The c statistic measured the ability of 
the model to differentiate between patients who reached 
our composite endpoint and those who did not: values 
close to 1 indicated very good discriminative ability, while 
values close to 0·5 indicated poor discriminative ability. 
We also measured time-dependent ROC curves 3 years 
after onset, because this is the period reported as median 
survival.3 Calibration was assessed by calibration plots and 
quantified by the calibration-in-the-large and calibration 
slope statistic.28,29,34 A calibration slope of 1 in combination 
with a calibration-in-the-large of 0 indicated good overall 
calibration (appendix).
We did a complete case analysis and sensitivity analyses 
omitting frontotemporal dementia from the model, 
omitting the C9orf72 repeat expansion from the model, 
and using time of diagnosis as starting point for 
prediction. We compared predicted and observed curves 
for times to reach our composite endpoint for combined 
and individual cohorts as well as the effect of recalibration 
of the intercept on predictive performance in different 
cohorts.34 Five equal-sized prognostic groups were 
created based on the linear predictor of the model 
(20% of data per group): very short, short, intermediate, 
long, and very long times to our composite survival 
endpoint. A computer algorithm was applied to the full 
dataset to randomly select five patients from the 
five prognostic groups (in total 25 patients), illustrating 
application of the model to individual patients.
Because the internal–external cross-validation approach 
allows evaluation of external performance across multiple 
studies, we meta-analysed estimates of model 
performance and calculated 95% CI, using random-
effects meta-analyses.29 We also calculated 95% prediction 
intervals (PI) to quantify the range of model performance 
across different populations, which helped to assess the 
potential generalisability of the model.29
Prognostic models for predicting survival and related 
outcomes require adequate discrimination and calibration 
performance to be clinically useful. We therefore 
calculated the joint 95% PI and estimated the probability 
that the model would achieve a certain predefined c 
statistic and calibration slope in future patients (appendix).
Data sharing
For medical doctors, we are making our model freely 
available online. We report all parameters of the model in 
the appendix and further supporting information can be 
requested online or from the corresponding author.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Data were collected between Jan 1, 1992, and Sept 22, 2016, 
for 11 475 patients. The different cohorts had different 
start and end dates within this period (appendix). Total 
follow-up was 40 016 years and median follow-up time 
was 97·5 months (IQR 52·9–168·5). Patient chara-
cteristics are shown in table 1 and the appendix.
Based on backward elimination in the largest dataset 
(1936 patients), eight of the 16 candidate predictors were 
selected for the multivariable prediction model: age at 
onset (n=10000, 100% of bootstraps), FVC (7598, 76%), 
diagnostic delay (10000, 100%), ALSFRS-R slope 
(10000, 100%), bulbar onset (8094, 81%), definite 
Univariable HR* Multivariable HR†
Age at onset (years) 1·28 (1·25–1·31) 1·02 (1·02–1·03)
Diagnostic delay (months) 0·48 (0·46–0·49) 0·63 (0·59–0·68)‡
Progression rate (points per month) 3·05 (2·84–3·27) 3·19 (2·71–3·75)§
Forced vital capacity (%) 0·76 (0·72–0·80) 0·99 (0·99–0·99)
Bulbar onset ·· 1·25 (1·17–1·33)
Definite ALS¶ ·· 1·25 (1·16–1·34)
Frontotemporal dementia ·· 1·18 (1·01–1·37)
C9orf72 repeat expansion ·· 1·37 (1·19–1·57)
Data are hazard ratio (HR; 95% CI). All HRs were estimated using random-effects Cox models with the 14 ALS research 
centres as grouping factor for the random effects. This table is intended to provide an indication of the relative effects of 
the transformed predictors, and the random-effects Cox model differs from the Royston-Parmar proportional odds model 
that was used to generate the predictions. ALS=amyotrophic lateral sclerosis. ··=not transformed. *Using the different 
transformed continuous predictors, we made a comparison between the first and third quartile and report the univariable 
HRs (see appendix for applied transformations). This illustrates the relative effects of the continuous predictors after 
transformation. Because the last four variables were dichotomous, it was not possible to make a comparison between the 
first and third quartiles. †This column shows the HRs when all eight predictors were combined (more details in appendix). 
The HRs resulted from coefficients and thus did not rely on the quartiles that were used in the univariate HR column. 
‡Because of non-normally distributed data, a natural logarithm transformation was applied. §Because of non-normally 
distributed data, a square-root transformation was applied. ¶According to revised El Escorial criteria.
Table 2: Relative effects of transformed predictors
For the model see http://www.
encalssurvivalmodel.org
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ALS (7120, 71%), presence of frontotemporal dementia 
(7416, 74%), and the C9orf72 repeat expansion (8679, 87%). 
Results for variables that were not included in the model 
are reported in the appendix. Age at onset, ALSFRS-R 
slope, diagnostic delay, and FVC were transformed 
because of non-linear relationships with our composite 
survival endpoint (appendix); the relative effects of the 
predictors after transformation are presented in table 2. 
Using all imputed datasets, we showed that a proportional 
odds Royston-Parmar model with two internal knots, 
without time-dependent covariates, was most appropriate 
according to the Akaike information criterion and that a 
proportional odds model consistently outperformed a 
proportional hazard model (appendix).
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Figure 1: Univariate meta-analysis of predictive performance
Panel A shows the random-effects meta-analysis of discrimination as measured with the c statistic (time-dependent receiver operator characteristic [ROC] curves in the 
appendix). Panels B and C show the random-effects meta-analysis of calibration as measured with calibration slope (B) and calibration-in-the-large (C). A calibration 
slope of 1 in combination with a calibration-in-the-large of 0 indicated good overall calibration (calibration slope <1: predictions are too extreme; calibration slope >1: 
predictions are too similar; further details in the appendix). The black diamonds indicate the mean (95% CI) of the predictive accuracy. 95% prediction intervals (PI), 
which indicate predicted accuracy of the model in a single new dataset or patient, are presented as a numeric range (below the 95% CI). Panel D is the visual translation of 
A–C in prognostic curves showing the agreement between predicted and observed probability of reaching the composite endpoint as well as indicating good 
discriminative power of the model. The curves also illustrate the possibility to stratify patients in different groups based on their predicted prognosis on the day of 
diagnosis. Five equal-sized groups were created based on predicted time to our composite endpoint. Omitted cohort label indicates the cohort left out of the 
internal–external cross-validation, which was done once for all 14 different cohorts. 
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The internal-external cross-validation framework 
resulted in 14 cycles of model development and external 
validation (meta-analysis shown in figure 1 and 
appendix). The model was used to define five groups 
with distinct median predicted times (SE) and observed 
times (SE) in months to the composite survival outcome 
since symptom onset: very short 17·7 (0·20), 16·5 (0·23); 
short 25·3 (0·06), 25·2 (0·35); intermediate 32·2 (0·09), 
32·8 (0·46); long 43·7 (0·21), 44·6 (0·74); and very long 
91·0 (1·84), 85·6 (1·96; figure 1). Comparing the other 
groups with the group with very long times to our 
composite endpoint revealed hazard ratios (HR) of 15·29 
(95% CI 13·92–16·79) for the very short group, 
7·19 (6·53–7·91) for the short group, 4·30 (3·94–4·69) 
for the intermediate group, and 2·49 (2·30–2·70) for the 
long group). Visual inspection of calibration plots 3 years 
after onset showed good agreement between predicted 
and observed probability for most cohorts 
(n=11; appendix). Predicted and observed probabilities of 
reaching our composite endpoint for cohort-specific 
curves showed similar results as calibration plots 
(appendix). For the three cohorts in which agreement 
between observed and predicted times to our composite 
endpoint was suboptimal, recalibration of the baseline 
hazard improved calibration (appendix). Similar 
results were noted for complete case analysis (appendix). 
We assessed all possible two-way interactions 
(ie, eight covariates with one interaction comprising 
two of the eight covariates), which did not improve 
predictive accuracy (appendix). The probability of good 
external predictive performance of the model was 
estimated to be 100·0% for the c statistic and 97·1% for 
calibration slope. The joint (combined) probability of 
good performance was 98·3% (appendix). Compared to 
estimates of group level data, the model provides more 
accurate and precise predictions of times to our 
composite endpoint (figure 2).
Our prediction of time to our composite survival 
endpoint is based on the regression coefficients of the 
final prediction model (appendix) and can be tailored (ie, 
recalibration of the incept) for each of the 14 participating 
cohorts. To illustrate its potential use in clinical practice, 
we have provided examples of patients selected from our 
dataset and their associated predictions, including 
uncertainty at the patient level (figure 3) and provided 
worked examples (appendix). A large proportion of 
patients deviated from the median time to reach the 
composite survival endpoint (at the group level): 
six patients (24%) had a 75% chance of dying, having a 
tracheostomy, or having non-invasive ventilation for 
more than 23 h per day before the median time, whereas 
eight other patients (32%) had a 75% chance of living 
without tracheostomy or non-invasive ventilation for 
more than 23 h per day for longer than the median time. 
The sensitivity analyses showed that the prediction 
model also provided accurate predictions when patient-
level information about the presence of frontotemporal 
dementia or a C9orf72 repeat expansion was not available 
and similar results of predictions using date of onset 
versus date of diagnosis as starting point for prediction 
(appendix). A survey of patients’ preferences with regard 
to knowing their personalised prognosis is reported in 
the appendix.
Discussion
On the basis of data collected from 11 475 patients with 
ALS across Europe, we have developed and externally 
validated a model for prediction of survival without 
tracheostomy or non-invasive ventilation for more than 
23 h per day in individual patients. Using recently 
developed methods, we derived ranges of predictive 
performance across different settings (ie, population-
based vs referral-based cohorts) and patient populations, 
thereby providing evidence for the potential 
generalisability of our model. Medical doctors can use 
our model freely online to provide estimates of prognosis 
in individual patients with ALS, with the aim of 
facilitating its use in clinical practice and in innovative 
trial design.
Associations between predictors and survival ourcomes 
in ALS have previously been reported at the group level.6 
Attempts to translate predictive associations into 
estimates of survival outcomes in individual patients 
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Figure 2: Group predictions
Probability densities for times to our composite endpoint (y-axis) are shown for the five groups from figure 1D. 
The probability density (or distribution) is not evenly distributed over time, meaning that the largest number of 
patients are predicted to die at the time when the curve has the highest density, but there is a small chance that 
patients will survive without tracheostomy or non-invasive ventilation for more than 23 h per day for much 
longer—this is reflected by the long, thin tails on the right side of this figure. These predictions curves provide 
guidance for discussing prognosis with patients. Furthermore, if the prediction model is not used (dashed curve), 
estimates of group-level data (ie, average or median survival in ALS, without using a personalised prediction) will 
generally be overly positive for groups with short or very short times to the composite endpoint, overly negative 
for groups with long and very long times to the composite endpoint, or overly uncertain (for groups with 
intermediate times to the composite endpoint). The horizontal bars at the bottom provide the same information 
for the different groups, with dots representing median times to our composite endpoint, thick lines representing 
probability IQRs, and thin lines representing 10–90% probability intervals to reach our composite survival 
endpoint. This figure quantifies the uncertainty of individual predictions because, for example, a participant with a 
predicted very short time to our composite endpoint still has a 2% chance of surviving up to 5 years after onset 
without tracheostomy or non-invasive ventilation for more than 23 h per day.
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with ALS are, however, infrequent and external validation 
of such models remains elusive.35 It is acknowledged that 
the development of reliable prediction models requires 
access to large datasets, with at least 200 events for 
validation.8 Hence, the current meta-analysis of 
individual participant data is the first study in ALS to 
enable the investigation of a large number of predictors, 
combining them in a prediction model. This is the 
first prediction model in ALS that rigorously assessed 
discrimination and calibration performance across 
different populations. We identified sources of 
heterogeneity across the cohorts, and addressed 
transportability issues of the model.27,28 This enabled us to 
determine the likely performance when applying the 
model in clinical practice, and thus to assess its clinical 
use in local circumstances. Dependent on requirements 
and clinicians’ or patients’ preferences, the model can be 
applied using probabilities of survival without 
tracheostomy or non-invasive ventilation for more than 
23 h per day, prognostic groups, or point estimates. For 
clinical care, we prefer the first two options, because 
these provide the possibility of being realistic without 
being unduly negative (appendix). Because the probability 
distributions for times to our composite endpoint were 
skewed, point estimates might not be preferred for 
predictions in individual patients. Ranges will become 
wider for patients with longer times to our composite 
endpoint, owing to less steep prognostic curves.
Large-scale, European Union funded, collaborative 
projects, such as Euro-MOTOR, SOPHIA, and NETCALS 
encourage standardised and harmonised data collection 
between the three population-based registries 
(n=4776, 42%) and 11 referral-based patient registries 
(n=6699, 58%) that contributed data to our study.36,37 
Differences in standard of care and cultural or genetic 
background between registries were taken into account 
in our model by allowing cohort-specific adjustments for 
estimation of prognosis in individual patients.
Predictors and times to our composite endpoint are 
likely to differ between different populations, as shown 
in our study. This might be due to real differences 
between populations. Other possibilities might be 
referral bias in referral-based versus population-based 
registries, variable interpretation of diagnostic criteria, 
differences in standard care, cultural or genetic 
background, or a combination of these factors. 
For more on Euro-MOTOR see 
www.euromotorproject.eu
For more on SOPHIA see 
www.sophiaproject.eu
For more on NETCALS see 
www.jpnd.eu
Figure 3: Clinical applicability to individual patients
Characteristics of and predictions for 25 randomly selected participants with amyotrophic lateral sclerosis (ALS) are presented to illustrate application of the model to 
predict time to the survival composite endpoint for individual patients. Predictions are shown on the left and patient characteristics on the right. Median predicted 
times to the composite endpoint for individual patients are represented by the dots. The thick coloured lines represent 25–75% probability IQRs and the thin black 
lines represent 10–90% probability intervals. The vertical dashed line represents the median time to the composite endpoint (34·7 months). Predicted times to our 
composite endpoint differed substantially between patients, reflecting both heterogeneity in ALS and the ability of the proposed model to stratify patients according 
to their characteristics. +=present. –=absent. *Forced vital capacity (FVC) expressed as percentage of predicted (based on normative values for age, sex, and height). 
†Definite ALS determined according to revised El Escorial criteria. 
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Importantly, internal–external cross-validation in our 
study did not reveal that differences between populations 
affected predictive performance of our model. 
Furthermore, differences in times to our composite 
endpoint between cohorts could not be interpreted as 
being caused by a specific cohort.
A weakness of our study is that we did not include 
treatment with riluzole, the only effective drug with 
proven effect on survival, as a predictor in our model. 
Reliable information about its usage is missing in most 
registries, but is estimated to be at least 75% in Europe.13 
Although the effect of riluzole on survival (pooled 
HR 0·84, based on a Cochrane meta-analysis)14 is more 
than ten times smaller than the combined effect of 
predictors in our proposed model (HR up to 15·29), 
incorporating riluzole use as well as other treatments, 
such as ventilation or gastrostomy, into our model will 
allow further tailoring of predictions.
Missing data, which is inherent to observational data, 
can lead to biased results when not appropriately 
addressed. We therefore used imputation methods that 
are proven to prevent such biases, even if a predictor is 
completely missing from one or more cohorts.32 Using 
internal–external cross-validation, we rigorously assessed 
the model’s predictive performance in external datasets. 
This approach not only allows assessment of the model’s 
overall performance in new patients, but also to establish 
whether performance is consistent across the different 
cohorts. Internal–external cross-validation therefore helps 
to determine to what extent model generalisability might 
be affected by differences in definition of endpoint, in 
collection of FVC versus SNIP or ALSFRS versus 
ALSFRS-R data, in possible recall bias of disease onset, in 
recruitment of patients between cohorts, in heterogeneity 
of disease characteristics between cohorts, or in the 
presence of unmeasured confounders. Although we did 
not aim to study such differences between cohorts and we 
can only speculate about possible causes (eg, intrinsic 
differences of ALS between cohorts, or extrinsic 
differences due to possible differences in, eg, clinical 
care), these differences did not appear to reduce the 
predictive performance of our proposed prediction model.
Our online model is ethically sensitive and demands 
thoughtful implementation. It might support clinicians in 
helping patients to maintain a degree of autonomy and 
help them in planning their lives. Our survey showed that 
some patients preferred to be informed about their 
personalised life expectancy (appendix). This is in line 
with previous reports in cancer medicine.38 The ethical 
aspects of tailored predictions in ALS or other 
neurodegenerative diseases have not been studied before, 
but from cancer medicine it is known that early 
discussions about goals of care are associated with better 
quality of life, reduced use of non-beneficial medical care 
near death, enhanced goal-consistent care, positive family 
outcomes, and reduced costs.39 However, many cancers 
have several modes of therapy, whereas ALS is still an 
incurable disease. Furthermore, the outcomes of the 
administered questionnaire might differ in patients from 
other cultural backgrounds; a selection bias might be 
present in the patients who responded to the survey; and 
patients might not foresee all consequences of the 
knowledge, and might regret asking to be informed if the 
predicted time to death, tracheostomy, or non-invasive 
ventilation for more than 23 h per day they receive is 
shorter than expected. To minimise the risk of such 
potential harm, the model will be accessible online only to 
medical doctors who have to register and sign in before 
access is provided. Professional health-care providers 
might use our model to determine the intensity of care 
pathways and to tailor counselling of individual patients 
and their caregivers. Prediction models might improve 
clinical trial design in two ways: use of the predicted 
outcome as an inclusion criterion instead of arbitrary 
eligibility criteria and use of predicted prognosis instead 
of a limited set of prognostic variables to stratify 
randomisation, thereby creating more homogeneous 
strata and greater statistical power to detect an effect. This 
was, for example, previously shown in patients with 
glioblastoma who have methylation of the MGMT 
(O⁶-methylguanine–DNA methyltransferase) gene.40
In accordance with the TRIPOD statement,10 all 
parameters and equations of our model were provided 
(appendix) to allow improvement of predictions through 
continuing research into other prognostic factors (eg, wet 
or imaging biomarkers or newly discovered genetic 
mutations) or implementation of outcome measures 
other than our composite survival endpoint (eg, being 
wheelchair-bound or other specific loss of function). This 
should also facilitate validation of our model in registries 
from a non-European background and its application in 
clinical trial populations.
In conclusion, we have developed and externally 
validated a model for prediction of survival without 
tracheostomy or non-invasive ventilation more than 23 h 
per day in individual patients with ALS. We have shown 
the generalisable and robust predictive performance of 
this model and made it freely available online. The 
outcomes of this study have the potential to facilitate 
tailored care and trial design, which will hopefully lead to 
a more successful discovery of effective treatments for 
patients with this devastating disease.
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